Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Saudi Arabia: Systematic Review and Meta-analysis.
diabetes type 2
kingdom of saudi arabia (ksa)
non-alcoholic fatty liver
prevalence
systematic review and meta analysis
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
accepted:
12
06
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Liver disease is fast emerging as a global health priority. Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries, with an increasing prevalence associated with the rising prevalence of diabetes mellitus and obesity. The worldwide prevalence of NAFLD may be in the order of 25%, but in the Middle East, it may be even higher. This study aimed to estimate the prevalence of NAFLD in the Kingdom of Saudi Arabia (KSA). A systematic review and meta-analysis were undertaken. Electronic searches were carried out through Medline, EMBASE, CINAHL, Web of Science, and Google Scholar, for articles from inception to April 2020. Studies conducted on adult populations in any setting reporting NAFLD prevalence were included. Pooled proportions and associated 95% confidence intervals (CIs) were presented in forest plots using a random effect model. Eight studies, including 4045 participants, were included. The pooled prevalence of NAFLD among all adult populations in KSA was 16.8% (11.1%-22.5%). Amongst those with type 2 diabetes, the prevalence was 58.0% (45.0%-70.9%). There were no true general population studies of the prevalence of NAFLD in KSA available. This review suggests that NAFLD is common in the KSA, and that type 2 diabetes is a risk factor in KSA as identified elsewhere in the world.
Identifiants
pubmed: 37448425
doi: 10.7759/cureus.40308
pmc: PMC10337700
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e40308Informations de copyright
Copyright © 2023, Alenezi et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Ann Hepatol. 2009;8 Suppl 1:S4-8
pubmed: 19381118
Liver Int. 2014 Jul;34(6):e128-35
pubmed: 24118857
Lancet. 2016 Jun 11;387(10036):2383-401
pubmed: 27174305
BMC Gastroenterol. 2021 Jun 1;21(1):245
pubmed: 34074270
Arab J Gastroenterol. 2018 Dec;19(4):166-179
pubmed: 30420265
Res Synth Methods. 2010 Apr;1(2):97-111
pubmed: 26061376
Radiology. 2006 Apr;239(1):105-12
pubmed: 16484355
World J Hepatol. 2015 Apr 8;7(4):638-48
pubmed: 25866601
Ann Saudi Med. 2012 May-Jun;32(3):288-92
pubmed: 22588441
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
Saudi J Gastroenterol. 2018 Jul-Aug;24(4):211-219
pubmed: 29956688
Int J Endocrinol. 2012;2012:902873
pubmed: 22851968
Saudi J Gastroenterol. 2012 Nov-Dec;18(6):349-57
pubmed: 23150019
Medicine (Baltimore). 2017 Sep;96(39):e8179
pubmed: 28953675
Diabetes Care. 2003 Dec;26(12):3351-2
pubmed: 14633828
Br J Radiol. 1992 Sep;65(777):774-8
pubmed: 1393413
World J Gastroenterol. 2017 Sep 28;23(36):6549-6570
pubmed: 29085205
Arch Iran Med. 2013 Oct;16(10):584-9
pubmed: 24093139
Hepatology. 2019 Jun;69(6):2672-2682
pubmed: 30179269
J Hepatol. 2019 Jan;70(1):151-171
pubmed: 30266282
Dig Dis Sci. 2016 May;61(5):1214-25
pubmed: 27038448
J Med Virol. 2013 Sep;85(9):1518-22
pubmed: 23852676
J Assoc Physicians India. 2013 Jul;61(7):448-53
pubmed: 24772746
Curr Diabetes Rev. 2020;16(3):204-210
pubmed: 31146665
Saudi Med J. 2015 Jul;36(7):785-6
pubmed: 26108580
Hepatology. 2016 Nov;64(5):1577-1586
pubmed: 27543837
Arab J Gastroenterol. 2015 Jun;16(2):54-8
pubmed: 26174761
Hepatology. 2017 Jun;65(6):2100-2109
pubmed: 28103626
East Mediterr Health J. 2014 Oct 20;20(10):589-95
pubmed: 25356689
Clin Med (Lond). 2013 Dec;13(6):576-9
pubmed: 24298105
Diabet Med. 2018 Mar;35(3):368-375
pubmed: 29247558
Liver Int. 2017 Jan;37 Suppl 1:81-84
pubmed: 28052624
Int J Environ Res Public Health. 2018 Nov 11;15(11):
pubmed: 30423871
Hepatology. 2019 Dec;70(6):1885-1888
pubmed: 31520407